2011 · Early external equity investment (historical) · $20 million ↗
Company history states that Merck KGaA provided an early investment in 2011; this is not the latest financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The website lists CaDAnCe-302 for tacabrutideg/BGB-16673 as Phase 3. CDAC is the company's term for chimeric degradation-activating compounds.
2026 conference materials include Phase 1 updates in previously treated CLL and other B-cell malignancies.
Program / service
Target / indication
Representative stage
Evidence & scope
tacabrutideg / BGB-16673
BTK · B-cell malignancies including CLL / SLL
Phase 3
Human results reported by the source; see facts and original materials for type and quality
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Stages must be separated by indication. Phase 3 initiation does not establish endpoint achievement or approval. Peer-company trade secret litigation is ongoing; no outcome is presumed.
